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We provide evidence that the Unc-51-like kinase 1
(ULK1) is activated during engagement of the type I
interferon (IFN) receptor (IFNR). Our studies demon-
strate that the function of ULK1 is required for gene
transcription mediated via IFN-stimulated response
elements (ISRE) and IFNg activation site (GAS) ele-
ments and controls expression of key IFN-stimulated
genes (ISGs). We identify ULK1 as an upstream
regulator of p38a mitogen-activated protein kinase
(MAPK) and establish that the regulatory effects
of ULK1 on ISG expression are mediated possibly
by engagement of the p38 MAPK pathway. Impor-
tantly, we demonstrate that ULK1 is essential for
antiproliferative responses and type I IFN-induced
antineoplastic effects against malignant erythroid
precursors from patients with myeloproliferative
neoplasms. Together, these data reveal a role for
ULK1 as a keymediator of type I IFNR-generated sig-
nals that control gene transcription and induction
of antineoplastic responses.
INTRODUCTION
Type I interferons (IFNs) are cytokines with important antitumor,
antiviral, and immunomodulatory properties (Gonza´lez-Navajas
et al., 2012; Bekisz et al., 2013, Platanias, 2005). These cytokines
have clinical activity against viral infections and several human
malignancies (Hervas-Stubbs et al., 2011; Bekisz et al., 2013;Kotredes and Gamero, 2013; Platanias, 2013; Stein and Tiu,
2013). Despite continuing efforts to define the precise mecha-
nisms by which IFNs generate antineoplastic responses, the
sequence of events and the specific coordination of different
IFN-activated signaling cascades required for such responses
remain incompletely defined (Platanias, 2013).
All type I IFNs bind to type I IFN receptor (IFNR), the engage-
ment of which activates JAK-STAT (Janus-activated kinase-
signal transducer and activator of transcription) signaling
pathways (Platanias, 2005; Stark and Darnell, 2012; Ivashkiv
and Donlin, 2014). Beyond these pathways, activation of
several other IFN-signaling cascades occurs during engage-
ment of IFN receptors, including the p38 mitogen-activated
protein kinase (MAPK) pathway (Uddin et al., 1999; Li et al.,
2004), the phosphatidylinositol 3-kinase (PI3K)-AKT pathway
(Kaur et al., 2008a, 2008b), and the mammalian target of rapa-
mycin complex 1 (mTORC1) and mTORC2 signaling cascades
(Kaur et al., 2007, 2012, 2014). The functions of these pathways
are essential for optimal transcription and/or mRNA translation
of various interferon-stimulated genes (ISGs) that are needed
for the induction of IFN-responses (Kaur et al., 2007, 2008b,
2014).
Although the relevance and functional importance of
mTORC1 signals in promoting functional IFN responses is
well established (Kaur et al., 2007), the precise mechanisms
and distinct roles of downstream mTORC1 effectors in the pro-
cess remain to be defined. Previous work has demonstrated
that activated mTORC1 prevents autophagy by phosphoryla-
tion of serine 757 (Ser757) of Unc-51-like kinase 1 (ULK1)
and by disrupting the interaction between ULK1 and AMP-acti-
vated protein kinase (AMPK) (Kim et al., 2011). ULK1 and
ULK2 are the closely related mammalian homologs of theCell Reports 11, 605–617, April 28, 2015 ª2015 The Authors 605
serine/threonine autophagy-related (ATG) protein kinase ATG1,
the first identified ATG product in yeast, and both are involved
in the regulation of autophagy (Alers et al., 2012). In the present
study, we examined whether ULK1 is engaged in IFN signaling
and what role it plays in the induction of type I IFN-mediated
responses. Our studies provide evidence implicating ULK1 in
type I IFN signaling and transcriptional activation of ISGs and
define a mechanism by which such ULK1-mediated activity oc-
curs in the IFN system, possibly involving regulation/activation
of p38 MAPK.
RESULTS
Type I IFN-Induced Phosphorylation of ULK1 on Serine
757 Is AKT Dependent
In initial studies, we examined whether type I IFN treatment
induces phosphorylation of ULK1 in IFN-sensitive cells. Treat-
ment of different IFN-sensitive malignant hematopoietic cell
lines (U937, KT-1, and U266) with human IFNb induced phos-
phorylation of ULK1 at the mTORC1 phosphorylation site
(Kim et al., 2011), Ser757 (Figures 1A–1C). In contrast, there
was no IFNb-dependent induction of phosphorylation of ULK1
at Ser555 (Figures 1A–1C), the amino acid residue phosphory-
lated by AMPK (Bach et al., 2011). Previous studies have estab-
lished that the serine/threonine protein kinase AKT is activated
downstream of PI3K (Kaur et al., 2008a) and mTORC2 (Kaur
et al., 2012) during engagement of the type I IFNR and regulates
downstream engagement of mTORC1 (Kaur et al., 2008b).
We examined whether engagement of ULK1 in IFN-signaling
requires upstream AKT activity. For this, we determined the
effects of IFNb treatment on the phosphorylation of ULK1 using
Akt1/2 double-knockout (Akt1/2/) mouse embryonic fibro-
blasts (MEFs) (Peng et al., 2003). Treatment of Akt1/2+/+ MEFs
with mouse IFNb resulted in phosphorylation of ULK1 on
Ser757 (Figure 1D). However, IFNb-induced phosphorylation of
ULK1 on Ser757 was defective in Akt1/2/ MEFs (Figure 1D).
In contrast, there was no IFNb-dependent induction of phos-
phorylation of ULK1 at Ser555 in both Akt1/2+/+ and Akt1/2/
MEFs (Figure 1D). Together, these data suggest that upstream
AKT activity is essential for regulation of type I IFN-induced
phosphorylation of ULK1 on Ser757.
Requirement of ULK1/2 Activity for Transcriptional
Activation of Type I IFN-Stimulated Genes
Our data establish that ULK1 is activated via the type I IFNR.
As the generation of IFN responses depends on expression of
ISGs and their protein products (Darnell et al., 1994; Stark and
Darnell, 2012; Cheon et al., 2014), we initiated studies to
determine whether ULK1 controls type I IFN-dependent gene
transcription. Initially, we determined whether ULK1/2 activity
is required for transcriptional activation via IFN-stimulated
response elements (ISRE) or IFNg activation site (GAS) elements
in luciferase reporter assays, using MEFs with targeted disrup-
tion of both the Ulk1 and Ulk2 genes. For these studies, we
used Ulk1/2+/+ and Ulk1/2/ MEFs (Cheong et al., 2011), as
ULK1 and ULK2 kinases were previously shown to have at least
partially redundant functions in fibroblasts (Kundu et al., 2008;
Lee and Tournier, 2011). IFNb-dependent transcriptional activa-606 Cell Reports 11, 605–617, April 28, 2015 ª2015 The Authorstion via either ISRE or GAS elements was significantly reduced
in the absence of Ulk1 and Ulk2 expression (Figures 2A and
2B). To further define the role of ULK1/2 in ISG regulation, we
sought to identify IFN-inducible genes differentially expressed
in Ulk1/2+/+ and Ulk1/2/ MEFs, using genome Illumina micro-
arrays. Using principal component analysis (PCA) of differentially
expressed genes, we found that the three biological replicates of
gene expression profiles cluster together and that the control
and IFNb-treated Ulk1/2+/+ and Ulk1/2/ cells represent sepa-
rated groups (Figure S1A). Comparison of the transcriptomic
profiles revealed IFN-inducible expression of 356 genes in
Ulk1/2+/+ MEFs (Figure 2C), whereas only 264 genes were induc-
ible in Ulk1/2/MEFs (Figure 2D). Notably, although 225 genes
were induced in both Ulk1/2+/+ and Ulk1/2/MEFs (Figures 2E
and 2F), the expression of 84 of these genes was significantly
higher in the Ulk1/2+/+ MEFs compared to the Ulk1/2/ MEFs
(Figure 2F and Table S1, genes highlighted in red). 131 genes
were found to be induced only in the Ulk1/2+/+ MEFs (Figures
2E and 2G; Table S2), whereas 39 unique genes were induced
in the Ulk1/2/MEFs (Figures 2E and 2H; Table S3). The differ-
entially expressed genes betweenUlk1/2+/+ andUlk1/2/MEFs
were classified among biochemical pathways using the KEGG
database (Tables S4, S5, and S6). Most of the genes whose
transcriptional induction by IFNb treatment was defective
or decreased in Ulk1/2/ MEFs could be classified among
biochemical pathways that regulate adaptive and innate immu-
nity, as well as antiviral, antiproliferative, and pro-apoptotic
responses (Table S4, genes highlighted in red and green;
Table S5). In contrast, genes induced by IFNb only in Ulk1/2/
MEFs could be classified among biochemical pathways that
are involved in cell adhesion and DNA transcription (Table S6).
A functional gene network, generated using IPA 2014 software,
is shown in Figure S1B and demonstrates relationships among
the 215 genes whose expression is defective or decreased in
the absence of Ulk1/2.
In further studies, we confirmed the requirement for ULK1/2
activity in the expression of several key ISGs using qRT-PCR
(Figures 3A–3I). Among the genes whose expression was found
defective in the absence of Ulk1/2 were Cxcl10 (Zhang et al.,
2005) and Eif2ak2 (Garcı´a et al., 2006; McAllister and Samuel,
2009), both of which are involved in the induction of antiviral
effects and control of apoptosis. The induction of several other
genes whose function was necessary for generation for IFN bio-
logical responses was also defective in Ulk1/2/ cells, including
Irgm2 (Hunn et al., 2008), Gch1 (Rani et al., 2007; Alp and Chan-
non, 2004), Ifit3 (Schmeisser et al., 2010; Liu et al., 2011); Oasl2
(Zhu et al., 2014), Irf7 (Sharma et al., 2003; Honda et al., 2005;
Colina et al., 2008), Irf9 (Darnell et al., 1994; van Boxel-Dezaire
et al., 2006), and Isg54/Ifit2 (Yang et al., 2012) (Figures 3A–3I).
To determine whether ULK1 expression is required for transcrip-
tional activation of IFN-induced genes in other cell types, studies
were performed with human U937 cells in which ULK1 was
knocked down using specific small interfering RNAs (siRNAs)
(Figure 3J). We found decreased IFN-inducible mRNA expres-
sion of ISG15 and ISG54 (Figures 3K and 3L), genes with crucial
roles in the induction of IFN responses (Lenschow et al., 2007;
Yang et al., 2012), further establishing a key role for ULK1 in
type I IFN signaling.
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Figure 1. Engagement of the Type I IFN
Receptor Results in Phosphorylation of
ULK1 at Serine 757
(A–C) Effects of IFNb on the phosphorylation of
ULK1 in (A) U937, (B) KT-1, and (C) U266 cell lines.
(Left) Cells were left untreated or were treated with
human IFNb for 10 or 30 min, as indicated. Lysates
were analyzed by SDS-PAGE and immunoblotted
with an antibody against the phosphorylated form
of ULK1 on Ser757. Equal amounts of cell lysates
from the same experiment were resolved sepa-
rately by SDS-PAGE and immunoblotted with
antibodies against the phosphorylated form of
ULK1 on Ser555 or ULK1. (Right) Bands were
quantified by densitometry using ImageJ software,
and data are expressed as ratios of pSer757-ULK1
over total ULK1.
(D) Effects of IFNb on the phosphorylation of
ULK1 in Akt1/2+/+ and Akt1/2/MEFs. Cells were
left untreated or were treated with mouse IFNb
for 10 or 30 min, as indicated. Lysates were
analyzed by SDS-PAGE and immunoblotted with
an antibody against the phosphorylated form of
ULK1 on Ser757 and GAPDH. Short and longer
exposures of p-Ser757 ULK1 from the same blot
are shown. Equal amounts of cell lysates from
the same experiment were resolved separately
by SDS-PAGE and immunoblotted with antibodies
against the phosphorylated form of ULK1 on
Ser555 or ULK1.
Cell Reports 11, 605–617, April 28, 2015 ª2015 The Authors 607
A B
C D
E F
G H
Figure 2. Targeted Disruption of Ulk1/2 Gene Expression Impairs IFNb-Dependent Gene Transcription
(A and B) Ulk1/2+/+ and Ulk1/2/MEFs were transfected with an ISRE-luciferase construct (A) or an 83GAS-luciferase construct (B). 42 hr after transfection, the
cells were incubated for 6 hr in the presence or absence of mouse IFNb, and luciferase activity was measured. Data are expressed as fold increase of luciferase
activity in response to IFNb treatment over control untreated samples for each condition. Bar graphs show means ± SE of four independent experiments for (A)
(legend continued on next page)
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It has been extensively established that ULK1 regulates the
induction of autophagy (Kim et al., 2011; Russell et al., 2013).
In addition, there is also evidence for IFN-dependent induction
of autophagy (Ambjørn et al., 2013; Schmeisser et al., 2014).
We determined whether inhibition of autophagy modulates
IFN-dependent transcriptional activation. The effects of siRNA-
mediated knockdown of ATG5, a protein required in the early
stages of autophagosome formation (Mizushima et al., 2001),
were initially determined. No significant differences in IFN-
dependent Isg15, Isg54, and Irf9 mRNA expression were
observed between control cells and cells in which ATG5 was
knocked down (Figures 4A–4D). Consistent with this, treatment
of cells with the autophagy inhibitors chloroquine or bafilomycin
A1 (Klionsky et al., 2008) did not significantly affect ISG mRNA
expression (Figures 4E–4G), further establishing that ULK1 pro-
motes type I IFN-dependent transcriptional activation of key
target genes in an autophagy-independent manner.
ULK1 Mediates Type I IFN-Dependent Activation
of p38 MAPK
To define the mechanisms by which ULK1 activity may regulate
type I IFN-dependent transcriptional activation, we examined
whether it is required for activation of pathways that control
type I IFN-dependent transcriptional activation of sensitive
genes. As activation of Stat1 is essential for transcriptional
induction of genes that contain ISRE or GAS elements in their
promoters (Stark and Darnell, 2012), we first determined if
phosphorylation/activation of Stat1 is Ulk1/2 dependent in
MEFs. IFNb-dependent phosphorylation of Stat1 on serine
727 and tyrosine 701 was inducible in both Ulk1/2+/+ and
Ulk1/2/ MEFs (Figure 5A), indicating that the functions of
ULK1/2 are not required for type I IFN-induced activation of
Stat1. As Stat1 is a key type I IFN-regulated protein involved in
complexes that control both ISRE- and GAS-dependent tran-
scription, these studies suggested that the effects of ULK1/2
on type I IFN-inducible transcriptional activation are independent
of modulation of the classical STAT pathways.
Previous studies have demonstrated that the p38 MAPK
pathway complements the function of STAT pathways and
plays a critical role in type I IFN-induced transcriptional activa-
tion via both ISRE and GAS elements (Uddin et al., 1999, 2000;
Li et al., 2004). We examined the possibility that the effects of
ULK1/2 on ISG transcription are mediated by effects on p38and three independent experiments for (B), using technical triplicates in each exp
**p < 0.01).
(C–H) Differential expression of ISGs in Ulk1/2+/+ and Ulk1/2/ MEFs. Cells w
expression profiles of untreated MEFs were compared with those of IFNb-treate
BeadChips and Illumina iScan. (C and D) Volcano plots of differentially expressed
356 genes were differentially expressed between untreated and IFNb-treated U
untreated and IFNb-treated Ulk1/2/ cells (D). (E) Venn diagram showing the ge
2+/+ MEFs (red ellipse) and Ulk1/2/MEFs (black ellipse) after treatment with IFN
and Ulk1/2/MEFs upon IFNb treatment. Differences in the effects of IFNb treatm
genes are characterized by a less efficient IFNb-driven transcription in Ulk1/2/
(G) Hierarchical clustering of differentially expressed genes only in Ulk1/2+/+ MEF
(H) Hierarchical clustering of differentially expressed genes only in Ulk1/2/ ME
All annotations presented here are based on statistical analyses and are present
values < 0.05 are shown. See also Tables S4, S5, and S6 and Figure S1.MAPK activity. We found that IFNb-induced phosphorylation
of p38 MAPK was substantially decreased in Ulk1/2/ MEFs
as compared to Ulk1/2+/+ MEFs (Figure 5B). Additionally, this
defective p38 MAPK phosphorylation could be rescued by
ectopic re-expression of wild-type ULK1 (ULK1 WT), but not a
kinase-inactive ULK1 mutant (ULK1 K46I) (Egan et al., 2011)
(Figure 5C). Complementation of Ulk1/2/ MEFs with ULK1
WT also restored IFN-induced transcriptional activation via
GAS elements (Figure 5D). Moreover, we found that p38a
MAPK is phosphorylated by ULK1 kinase in in vitro assays
(Figures 5E and S2), further suggesting that p38MAPKmediates
the regulatory effects of Ulk1 in type I IFN-dependent transcrip-
tional activity.
ULK1/2 Activity Is Required for Induction of Type I
IFN-Dependent Antiviral and Antiproliferative Effects
To define whether the defective type I IFN-dependent gene
transcription seen in Ulk1/2/ MEFs has consequences in the
generation of antiviral responses by type I IFNs, the ability of
mouse IFNa to protect cells from encephalomyocarditis virus
(EMCV) infection was compared in Ulk1/2+/+ and Ulk1/2/
MEFs. Ulk1/2/ MEFs were much more sensitive to EMCV
infection compared to Ulk1/2+/+ MEFs (Figure S3). Specifically,
at least a 50-fold reduction in infective dose was required to
induce comparable EMCV-induced cytopathic effects (CPE)
in the Ulk1/2/ MEFs compared with the Ulk1/2+/+ MEFs
(Figure S3). Moreover, IFNa-induced antiviral dose-response
data indicated that Ulk1/2/ cells are also less responsive to
mouse IFNa treatment comparedwith Ulk1/2+/+ cells (Figure 6A).
Together, these data show that Ulk1/2/MEFs are more sensi-
tive to viral infection and less sensitive to the antiviral effects of
IFNa compared with Ulk1/2+/+ MEFs, establishing that engage-
ment of Ulk1/2 is required for the control of type I IFN-generated
antiviral responses in MEFs.
We also determined whether ULK1 is required for the genera-
tion of type I IFN-antiproliferative responses. For this purpose,
we performed studies involving siRNA-mediated knockdown of
ULK1 in U937 cells, followed by assessment of IFNb-inhibitory
responses on leukemic blast colony-forming unit (CFU-L) colony
growth. As shown in Figure 6B, inhibition of expression of ULK1
partially reversed suppression of CFU-L colony formation by
IFNb treatment, implicating ULK1 as a signaling element
required for the generation of type I IFN-antiproliferative effects.eriment. Statistical analyses were performed using Student’s t test (*p < 0.05;
ere incubated in the presence or absence of mouse IFNb for 6 hr. The gene
d MEFs in three independent experiments using MouseWG-6 v2.0 Expression
genes after IFNb treatment are shown for (C) Ulk1/2+/+ and (D) Ulk1/2/MEFs.
lk1/2+/+ cells (C), whereas 264 genes were differentially expressed between
ne expression overlap existing between differentially expressed genes in Ulk1/
b. (F) Hierarchical clustering of differentially expressed genes in both Ulk1/2+/+
ent between Ulk1/2+/+ and Ulk1/2/MEFs are seen for 87 genes; 84 of these
MEFs (see list of genes in Table S1).
s (see list of genes in Table S2).
Fs (see list of genes in Table S3).
ed with p values after false discovery rate correction. Only annotations with p
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Figure 3. Requirement of ULK1/2 Activity
for IFNb-Dependent Transcription
(A–I) Ulk1/2+/+ and Ulk1/2/ MEFs were left un-
treated or were treated with mouse IFNb for 6 hr.
(J–L) U937 human leukemia cells were transfected
with either control or ULK1 siRNAs. 24 hr after
transfection, the cells were either left untreated
or were incubated with human IFNb for 6 hr.
(J) Levels of ULK1 protein expression are shown,
using western immunoblotting, probing with
ULK1-specific antibody. The immunoblot was also
probed for GAPDH as a loading control.
(A–I, K, and L) qRT-PCR analyses of the relative
mRNA expression of ISGs after IFNb stimulation
in (A–I) Ulk1/2+/+ and Ulk1/2/MEFs and (K and L)
U937 cells after siRNA transfection are shown.
Expression levels of the indicated genes were
determined using GAPDH for normalization. Data
are expressed as fold change over untreated
samples (A–I) or control siRNA untreated samples
(K and L) and bar graphs represent means ± SE
of three independent experiments for (A)–(F) and
(L) and four independent experiments for (G)–(I)
and (K). Statistical analyses were performed using
Student’s t test between treated groups (*p < 0.05;
**p < 0.01; ***p < 0.001).
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D E
GF
CBA Figure 4. ULK1/2 Activity Regulates ISG
Transcription in an Autophagy-Independent
Manner
(A) Total cell lysates from MEFs transfected with
either control siRNA or ATG5-specific siRNA were
resolved by SDS-PAGE and immunoblotted with
anti-ATG5 or anti-GAPDH-specific antibodies, as
indicated.
(B–D) MEFs transfected with control siRNA or
ATG5-specific siRNA were treated with mouse
IFNb for 6 hr, and mRNA expression for the indi-
cated genes was assessed by qRT-PCR, using
GAPDH for normalization. Data are expressed as
fold change over control siRNA untreated (UT)
samples, and bar graphs represent means ± SE of
three independent experiments.
(E–G) MEFs were treated with chloroquine (CQ),
bafilomycin A1 (BFA), and/or mouse IFNb. mRNA
expression for the indicated genes was assessed
by qRT-PCR, using GAPDH for normalization.
Data are expressed as fold change over control
untreated (UT) cells, and bar graphs represent
means ± SE of five independent experiments
for (E) and (G) and three independent experiments
for (F).ULK1 Is Critical for IFN Regulation of Normal
Hematopoiesis and the Generation of IFN Responses
in Myeloproliferative Neoplasms
As type I IFNs are potent regulators of normal hematopoiesis
(Platanias, 2005), in subsequent studies, we determined if
engagement of ULK1 activity is necessary for the generation of
growth-inhibitory responses on normal CD34+-derived hemato-
poietic precursors. For this purpose, we used specific siRNAs to
knock down ULK1 expression in primary normal human bone
marrow progenitors and examined the effects of this knockdown
on the inhibitory effects of IFNa on CD34+-derived erythroid and
myeloid precursors. As expected, treatment with human IFNa
suppressed the growth of normal myeloid (granulocyte-macro-
phage colony-forming unit [CFU-GM]) and early erythroid
(erythroid burst-forming unit [BFU-E]) progenitors in clonogenic
assays in methylcellulose (Figure 7A). However, these suppres-
sive effects were reversed by ULK1 knockdown (Figure 7A), indi-Cell Reports 11, 605–6cating key and essential roles for ULK1 in
the control of normal hematopoiesis by
type I IFNs.
In further studies, we examined
whether the engagement of ULK1 by the
type I IFNR is essential for generation
of antineoplastic responses. It is well
established that polycythemia vera (PV)
and other Philadelphia-chromosome-
negative myeloproliferative neoplasms
(MPNs) are sensitive to type I IFN therapy,
and type I IFN treatment is currently used
for the treatment of such neoplasms
(Tefferi and Vainchenker, 2011; Kiladjian
et al., 2011; Cassinat et al., 2014). We
determined whether ULK1 is requiredfor generation of type I IFN-dependent growth-inhibitory effects
on malignant erythroid progenitors from patients with PV. When
primary peripheral blood mononuclear PV cells were treated
with IFNb, we observed induction of ULK1 phosphorylation
on serine 757 (Figure 7B). Importantly, when the effects of
type I IFN treatment on malignant erythroid progenitors from
five different MPN patients were assessed, we found that
siRNA-mediated targeted inhibition of ULK1 expression
reversed the suppressive effects of IFNb on primitive malignant
erythroid precursors in vitro (Figure 7C). Thus, ULK1 engage-
ment via the type I IFNR appears to be essential for generation
of antineoplastic effects in MPNs.
Next, we determined whether ULK1 expression is upregulated
in the peripheral blood of MPN patients. Specific analysis for
ULK1 gene expression from a previously reported microarray
profiling study in neutrophils from a cohort of patients with
chronic MPNs (Rampal et al., 2014) showed that ULK117, April 28, 2015 ª2015 The Authors 611
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Figure 5. ULK1/2 Activity Is Required for
Type I IFN-Dependent Activation of the p38
MAPK
(A) Ulk1/2+/+ and Ulk1/2/ MEFs were treated
with mouse IFNb as indicated. Equal amounts of
total cell lysates were resolved by SDS-PAGE and
consecutively immunoblotted with antibodies
against pSer727-STAT1, pTyr701-STAT1, and
STAT1, as indicated.
(B) Ulk1/2+/+ and Ulk1/2/ MEFs were treated
with mouse IFNb for 10 or 30 min, as indicated.
Equal amounts of total cell lysates were resolved
by SDS-PAGE and consecutively immunoblotted
with antibodies against the phosphorylated form
of p38 MAPK on Thr180/Tyr182 and against p38
MAPK. Short and longer exposures of p-Thr180/
Tyr182 p38 MAPK from the same blot are shown.
(C) Ulk1/2/ MEFs were transfected with
pcDNA6.2 empty vector (Vector) or ULK1 WT or
ULK1-K46I (kinase inactive) plasmids, as indi-
cated. 48 hr after transfection, the cells were
treated with mouse IFNb for 10 and 30 min, as
indicated. Equal amounts of total cell lysates were
resolved by SDS-PAGE and consecutively im-
munoblotted with the indicated antibodies.
(D) Ulk1/2/ MEFs were transfected with
pcDNA6.2 empty vector (Vector), or ULK1 WT
plasmids, as indicated. 24 hr after transfection,
these cells were transfected with an 83 GAS-
luciferase construct. 42 hr later, the cells were
incubated for 6 hr in the presence or absence
of mouse IFNb, and luciferase activity was
measured. Data are expressed as fold increase of
luciferase activity in response to IFNb treatment
over control untreated samples for each condition.
Bar graphs show means ± SE of three indepen-
dent experiments using technical triplicates in
each experiment. Statistical analyses were per-
formed using Student’s t test (*p < 0.05).
(E) U937 cells were starved overnight prior to IFNb
treatment and then treated with human IFNb for 5,
10, and 30 min, as indicated. After cell lysis, equal
amounts of protein were immunoprecipitated with
either ULK1-specific antibody or control non-im-
mune rabbit IgG (RIgG). In vitro kinase assays to
detect ULK1 activity were subsequently performed on the immunoprecipitates, using p38aMAPK recombinant inactive protein as an exogenous substrate. (Left
and top) Immunoblot demonstrating total immunoprecipitated ULK1 expression used in each condition for the in vitro kinase assay. (Left and bottom) Autora-
diography film demonstrating ULK1-induced phosphorylation of p38a MAPK after IFNb treatment is shown. Note: a lane between ULK1 and RIgG immuno-
precipitates was loaded with 13 loading dye for best separation between the wells. (Right) Bands were quantified by densitometry using ImageJ software, and
data are expressed as ratios of 32P p38a MAPK over total immunoprecipitated ULK1. See also Figure S2.expression is increased in different groups of MPN patients,
including patients with PV, essential thrombocythemia (ET),
and myelofibrosis (MF) (Figure 7D). The upregulation of expres-
sion of ULK1 was also seen in another independent group of
MPN patients (Figure 7E) using RT-PCR analysis for ULK1
mRNA expression, establishing upregulation of ULK1 expres-
sion in MPNs and suggesting a mechanism to explain the unique
sensitivity of these neoplasms to the effects of type I IFNs.
DISCUSSION
Type I IFNs are cytokines with important biological effects in vitro
and in vivo and have been used extensively in the treatment of612 Cell Reports 11, 605–617, April 28, 2015 ª2015 The Authorsvariousmalignancies, viral syndromes, and autoimmune disease
in humans (Borden et al., 2007; Cheon et al., 2014; Platanias,
2013). The important biological and therapeutic properties of
type I IFNs reflect the induction of expression of key genes via
the type I IFNR that mediate diverse biological responses,
including antineoplastic, immune modulatory, and antiviral ef-
fects (Cheon et al., 2014; Kroczynska et al., 2014). The precise
mechanisms accounting for the transcriptional activation and
mRNA translation of such ISGs have been the focus of extensive
work that led to the original discovery of JAK-STAT pathways
(Darnell et al., 1994; Platanias, 2005; Stark and Darnell, 2012).
Besides the classical JAK-STAT signaling cascades, the type I
IFNR engages several other cellular pathways in normal and
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Figure 6. Regulation of Type I IFN Responses by ULK1/2 Activity
(A) Ulk1/2+/+ and Ulk1/2/ MEFs were seeded in quadruplicate in individual
wells of 96-well plates and then treated with mouse IFNa for 16 hr, as indi-
cated. Ulk1/2+/+ cells were subsequently challenged with a 1:2 3 104 dilution
of encephalomyocarditis virus (EMCV) and the Ulk1/2/ cells with a 1:106
dilution of EMCV. EMCV-induced cytopathic effects (CPEs) were determined
24 hr later. The data are expressed as percent protection from CPEs adjusted
to viral infective dose (% protection-AVI). Values shown represent means ± SD
of two independent experiments. See also Figure S3.
(B) U937 cells were transfected with either control siRNA or ULK1 siRNA, and
leukemic CFU-L colony formation was assessed in clonogenic assays in
methylcellulose in the presence or absence of human IFNb, as indicated.
Data are expressed as percent colony formation of control siRNA-transfected
untreated cells, and bar graphs represent means ± SE of five independent
experiments. Statistical analysis was performed using Student’s t test
(*p < 0.05).malignant cells (Platanias, 2005; van Boxel-Dezaire et al., 2006;
Gonza´lez-Navajas et al., 2012), the functions of which are
required for the generation of type I IFN-dependent biological re-
sponses (Platanias, 2005). Among them, the p38MAPK cascade
appears to act as an auxiliary pathway, necessary for optimal
transcription of ISGs, without modulating elements of the
STAT-pathway (Platanias, 2005). Despite a better understanding
of the mechanisms of type I IFN signaling in the past decades,
several questions have remained unanswered, particularly
the mechanisms that define signaling specificity. Although,
in some cases, selective use of the type I IFNR subunits may
account for differential gene expression among distinct type I
IFNs (de Weerd et al., 2013), the precise effectors of suchspecific pathways and the potential interactions with other cyto-
kine receptors remain to be defined (Kaur and Platanias, 2013).
Also, there is a need to identify cellular elements linking path-
ways that control IFN-dependent gene transcription to the
ones that regulate subsequent mRNA translation of ISGs, as
this should allow better understanding of the mechanisms that
account for specificity of expression of ISG products.
In the present study, we provide evidence that the kinase
ULK1 is phosphorylated by engagement of the type I IFNR at
serine 757, an mTORC1 phosphorylation site known to inhibit
ULK1 in pathways that control the initiation of autophagy (Kim
et al., 2011). Furthermore, our data show that ULK1 is activated
after engagement of the type I IFNR and that its activated form
can, either directly or through intermediate kinases, phosphory-
late the p38 MAPK in immune complex kinase assays in vitro.
This suggests that during type I IFN treatment, the pro-autopha-
gic functions of ULK1 are blocked, and instead, ULK1 activity
is possibly re-directed toward regulation of the p38 MAPK
pathway. Consistent with this, type I IFN-inducible activation
of the p38 MAPK pathway is defective in cells with targeted
disruption of the Ulk1/2 genes and appears to result in defective
downstream ISG transcription. Moreover, type I IFN-induced
activation of p38 MAPK and transcriptional activation via GAS
elements is restored by ectopic expression of ULK1 WT protein
in Ulk1/2/ MEFs. Hence, it is possible that for optimal activa-
tion of p38 MAPK pathway in the type I IFN system, the activities
of both ULK1 and MKK3/6 (Li et al., 2005) are required. Notably,
the effects of ULK1 on ISG expression appear to reflect selective
regulation of the p38 MAPK pathway, as functional engagement
of STAT1 is intact in Ulk1/2/ cells.
In previous studies, we had demonstrated that AKT is required
for mRNA translation of ISGs, but not ISG transcription (Kaur
et al., 2008b). In the present study, we provide evidence that
Akt1/2 activity is required for type I IFN-inducedULK1 phosphor-
ylation at serine 757. Furthermore, given that transcription of
ISGs is defective in Ulk1/2/ MEFs and in U937 cells in which
ULK1 has been knocked down, it is possible that another type
I IFN-activated kinase(s) act(s) upstream of ULK1 during engage-
ment of the type I IFNR, and concomitant regulation of ULK1
by such kinase may be necessary for the transcriptional activity
of ULK1. Some examples of possible kinases are PKC-d and
ERK1 kinases, which have been identified as potential kinases
of ULK1 (Mack et al., 2012) and are activated downstream of
type I IFNR (Platanias, 2005), but this remains to be determined
in future studies.
The potential engagement of ULK1 in type I IFN signaling has
important functional implications for the generation of the
effects of type I IFNs. Our studies provide evidence for an
involvement of ULK1 in the induction of both type I IFN-antiviral
responses and growth-inhibitory activities. They also suggest
key and essential roles for ULK1 in the generation of the suppres-
sive regulatory effects of type I IFNs on normal hematopoiesis,
by demonstrating that ULK1 knockdown reverses suppression
of myeloid (CFU-GM) and early erythroid (BFU-E) hematopoietic
progenitors. Most importantly, our data identify ULK1 as an
essential element for the generation of the antineoplastic effects
of type I IFNs on primitive malignant hematopoietic precursors
from patients with PV, an MPN where IFN treatment has majorCell Reports 11, 605–617, April 28, 2015 ª2015 The Authors 613
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Figure 7. Requirement of ULK1 for the Reg-
ulatory Effects of Type I IFNs on Normal and
Malignant Human Hematopoiesis
(A) Normal human bone marrow-derived CD34+
cells were transfected with either control siRNA
or ULK1 siRNA and incubated in clonogenic
assays in methylcellulose in the presence or
absence of human IFNa, and myeloid (CFU-GM)
and erythroid (BFU-E) progenitor colony forma-
tion was assessed. Data are expressed as
percent colony formation of control siRNA-
transfected untreated cells and represent
means ± SE of three independent experiments.
Statistical analysis was performed using Stu-
dent’s t test (*p < 0.05).
(B) (Left) Serum-starved circulating primary pe-
ripheral blood mononuclear cells from a patient
with PV were treated with human IFNb for 10
or 30 min, as indicated. Total cell lysates were
resolved by SDS-PAGE and consecutively im-
munoblotted with p-S757 ULK1 and ULK1 anti-
bodies. The immunoblot was also probed for
GAPDH as a loading control. (Right) Bands were
quantified by densitometry using ImageJ soft-
ware, and data are expressed as ratios of p-ULK1/
ULK1.
(C) Peripheral blood mononuclear cells from pa-
tients with PV were transfected with either control
siRNA or ULK1 siRNA, and the effects of human
IFNb on malignant erythroid (BFU-E) colony for-
mation were assessed by clonogenic assays in
methylcellulose. Data are expressed as percent
colony formation of control siRNA-transfected
untreated cells and represent means ± SE of
five independent experiments, using cells from
five different patients with PV.
(D) Boxplot shows gene expression of ULK1 in
neutrophils in a large independent cohort of
normal individuals (normal, n = 11) and patients
with PV (n = 13), ET (n = 24), and MF (n = 18).
Statistical analyses were performed using Student’s t test comparing expression in each MPN group to the normal group (**p < 0.01; ***p < 0.001).
(E) qRT-PCR analysis for ULK1 mRNA expression in neutrophils isolated from different patients with MPNs (MPN1-8) and age-matched controls (CTRL1-4).
Expression levels of the ULK1 gene were determined using GAPDH for normalization. Data are expressed as fold change over CTRL4, and bar graphs represent
means ± SD for two independent assays.clinical activity (Tefferi and Vainchenker, 2011). Remarkably,
when expression of ULK1 mRNA was specifically analyzed in a
large cohort of patients with different MPNs, we found significant
increases in ULK1 expression in different subtypes of MPNs,
including PV, essential thrombocytosis, andmyelofibrosis. There
is prior evidence that the p38 MAPK pathway is involved in the
generation of type I IFN-antileukemic effects (Mayer et al.,
2001), while other studies have shown that p38 MAPK activation
is essential for the generation of the inhibitory effects of type I
IFNs on JAK2V617F-positive hematopoietic progenitor cells
from MPN patients (Lu et al., 2010). Our findings suggest a
mechanism by which ULK1 and p38 MAPK are engaged in
type I IFN-signaling in MPNs and, most importantly, provide an
explanation for the unique sensitivity of these malignancies to
the effects of type I IFNs, due to overexpression of ULK1.
It should be noted that in a recent study, ULK1 was shown to
inhibit STING activity, leading to inhibition of IRF3, and conse-
quent suppression of type I IFN production (Konno et al., 2013).614 Cell Reports 11, 605–617, April 28, 2015 ª2015 The AuthorsThese events appear to function as a negative-feedback con-
trol mechanism to prevent sustained transcription of ISGs
(Konno et al., 2013) and limit development of IFN-dependent
autoimmune inflammatory disorders (Gall et al., 2012). The
results of our studies, taken in context with the report of Konno
et al. (2013), suggest a dual regulatory role for ULK1 in the con-
trol of type I IFN responses, acting as a ‘‘molecular switch’’
in the IFN system that regulates the balance and duration of
IFN biological responses. In this model, ULK1 appears to regu-
late directly early signals that control ISG expression and in-
duction of type I IFN responses. At the same time, a more
delayed ULK1-mediated effect appears to be the suppression
of type I IFN production by suppressing STING activity, thus
limiting/optimizing the response. The recognition of this unique
role for ULK1 should have important clinical-translational impli-
cations, as modulation of ULK1 activity may be used as an
approach to selectively enhance the activity of type I IFNs on
MPN cells.
EXPERIMENTAL PROCEDURES
Materials and some of the methods can be found in the Supplemental Exper-
imental Procedures.
Cells and Cell Culture
U937, U266, and KT-1 cells were grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS) and antibiotics. The immortalized Akt1/2+/+
and Akt1/2/ MEFs were kindly provided by Dr. Nissim Hay (University of
Illinois at Chicago) (Peng et al., 2003). The immortalized Ulk1/2+/+ and Ulk1/
2/ MEFs have been described previously (Cheong et al., 2011). MEFs
were cultured in DMEMmedium supplemented with 10% FBS and antibiotics.
Peripheral blood from patients with PV was collected after obtaining consent
approved by the institutional review board of Northwestern University.
Additionally, blood samples were collected from patients with MPNs and
controls at Albert Einstein School of Medicine, under an institutional review
board-approved study.
Immunoblotting
Cells were treated, transfected, and lysed as described in Supplemental
Experimental Procedures. Equal amounts of total cell lysates were resolved
by SDS-PAGE and processed for immunoblotting essentially as in our previ-
ous studies (Uddin et al., 1999; Kaur et al., 2007; Kroczynska et al., 2009).
Luciferase Reporter Assays
Ulk1/2+/+ and Ulk1/2/ MEFs were co-transfected with a b-galactosidase
expression vector and either an ISRE-luciferase or 8X GAS-luciferase
construct. Luciferase activities were measured and normalized to b-galactosi-
dase activity as in previous studies (Uddin et al., 1999). See Supplemental
Experimental Procedures for a detailed description.
Microarray Analysis
Total RNA was isolated from Ulk1/2+/+ and Ulk1/2/ MEFs untreated or
treated with IFNb (n = 3), and labeled cRNA was hybridized to MouseWG-6
v2.0 Expression BeadChips. See Supplemental Experimental Procedures for
a detailed description.
qRT-PCR
qRT-PCR was carried out using commercially available 6-carboxyfluorescein-
labeled probes and primers (Applied Biosystems). The mRNA amplification
was calculated as described previously (Kaur et al., 2007), and the data
were plotted as the increase of fold change as comparedwith control samples.
See the Supplemental Experimental Procedures for a detailed description.
Immunoprecipitations and In Vitro Kinase Assays
In vitro kinase assays to detect ULK1 kinase activity in cells treated with IFNb
were performed essentially as in previous studies (Kroczynska et al., 2009).
MAPK14 (p38a MAPK) recombinant human inactive protein was used as an
exogenous substrate. See the Supplemental Experimental Procedures for a
detailed description.
Antiviral Assays
The antiviral effects of mouse IFNa on Ulk1/2+/+ and Ulk1/2/ MEFs were
determined in assays using ECMV as the challenge virus, as in previous
studies (Kaur et al., 2012).
Hematopoietic Cell Progenitor Assays
The effects of ULK1 knockdown were assessed in leukemic (CFU-L), erythroid
(BFU-E), or myeloid (CFU-GM) colony formation using clonogenic assays
in methylcellulose (STEMCELL Technologies) in the absence or presence
of type I IFNs, as in previous studies (Mayer et al., 2001; Joshi et al., 2009;
Kroczynska et al., 2012; Mehrotra et al., 2013; Kaur et al., 2014). See the
Supplemental Experimental Procedures for a detailed description.
Statistical Analyses
Student’s t test was used for comparison of one observation between two
groups. One-way ANOVA was used to compare more than two groupsfollowed by Tukey’s test. Differences were considered statistically significant
when p values were less than 0.05.ACCESSION NUMBERS
The NCBI GEO accession number for the microarray data reported in this
paper is GSE60778.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.03.056.
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